Introduction
============

The habenula, located in the epithalamus, links midbrain and hindbrain regions to the forebrain. It's considered to be at a crossroads, allowing it to act as a conductor of cognitive behaviors ([@B55]; [@B40]). Landmark work in monkeys by [@B63] found that habenula neurons provide negative reward signals to midbrain dopamine neurons. Human functional neuroimaging results also find that the habenula encodes negative motivational value ([@B53]). However, due to its small size and accessibility, most information about the habenula is derived from animal studies. Specifically, the habenular connections to the dopamine and serotonin systems; and its associations with motivation have spurred its study in animal models of depression and addiction. These studies have been reviewed in the context of psychiatric disease ([@B39]; [@B85]; [@B21]), drug addiction ([@B54]; [@B101]; [@B64]) and withdrawal ([@B65]).

At the molecular level, gene expression images and profiles of the mouse and rat brain have been used to characterize the habenula ([@B102],[@B103]). By determining which genes are specifically expressed in the habenula these studies have been able to define subregions and link molecular processes. In the human brain, transcriptomic profiling has been used to characterize genes differentially expressed in postmortem studies of depression, addiction, and other psychiatric diseases. However, these studies commonly focus on the frontal cortex or limbic regions ([@B70]; [@B14]; [@B18]; [@B51]). While the habenula has been linked to psychiatric disease, its transcriptional profile has not been analyzed in normal or diseased brains beyond a comparison of the 100 most specifically expressed genes ([@B6]).

Large-scale efforts by the Allen Institute for Brain Science and their collaborators have led to the creation of genome-wide gene expression atlases of the human brain ([@B37]; [@B67]). These atlases are anatomically comprehensive, providing transcriptomic profiles of over 200 regions that include the lateral and medial habenula. Unlike past studies of the human habenula which are limited by the resolution of MR imaging, this transcriptomic data enables analysis at the molecular scale.

In this present study, we used human transcriptomic data to determine which genes are specifically expressed in the lateral and medial habenula. We sought to learn if these genes were associated with addiction and depression relative to other brain regions. We also took a broader approach by assessing which cellular components, molecular processes, or functions and disease-associated genes were uniquely expressed in the habenula.

Materials and Methods {#s1}
=====================

Adult Human Brain Gene Expression Data
--------------------------------------

Gene expression data that comprehensively covers the adult human brain was obtained from the Allen Human Brain Atlas ([@B37]). From the six brains assayed in the Atlas, we used only data from the three that had habenula samples (all male). Specifically, the lateral and medial habenula was acquired from two donor brains (ID:9861/H0351.2001, 24 years old; ID:12876/H0351.1009, 57 years old), and one with only a lateral sample (ID:15697/H0351.1016, 55 years old). Postmortem blood was tested for the presence of therapeutic drugs and drugs with abuse potential by the Allen Institute. Caffeine (all 3 donors), theobromine (2 donors), and atropine (1 donor) were detected in the donors at levels that are not considered toxicologically significant. The expression data were extensively annotated and normalized by the Allen Institute for Brain Science (adjusted for array-specific biases, batch, and dissection method). Data from the three donor brains contained 2,674 spatially resolved gene expression profiles, providing expression information for 217 unique named brain regions. Custom 64K Agilent microarrays were used to assay genome-wide expression. The 58,692 probes were filtered to 48,170 that mapped to a gene symbol in the Allen annotations. Details of the procedures used by the Allen Institute researchers are available in the Allen Human Brain Atlas technical white paper^[1](#fn01){ref-type="fn"}^.

Prenatal Human Gene Expression Data
-----------------------------------

The BrainSpan consortium has created a similar transcriptomic atlas for the normal mid-gestational human brain ([@B67]). The medial and lateral habenular nuclei were acquired in all four of the prenatal specimens used for this atlas (15--21 postconception weeks, 3 females and one male). These four specimens passed several exclusion criteria and no neuropathological defects were found by the consortium. Data from the four specimens contained 1,203 spatially resolved gene expression samples, providing expression information for 516 unique named brain regions. The same custom 64K Agilent microarrays that were used for the adult atlas were used to profile expression. Details of the procedures used by the Allen Institute researchers are available in the Brainspan Atlas of the Developing Human Brain technical white paper^[2](#fn02){ref-type="fn"}^.

Region-Specific Expression Analysis
-----------------------------------

The limma software package was used to detect probes that are specifically expressed in the lateral and medial habenula ([@B88]). For each microarray probe, linear models were fit with coefficients for donor and region of interest for the lateral and medial habenula separately. In other words, expression of given probe across the complete set of expression measurements (adult: 2,674, fetal: 1,203) was predicted with a donor indicator variable and if the sampled region was the lateral and medial habenula (calculated separately). The empirical Bayes moderation method implemented in limma was used to calculate moderated t statistics and corresponding *p*-values (shrinks variances to a common value).

Estimation of Cell-Type Proportion
----------------------------------

The markerGeneProfile (MGP) R package was used to estimate cell type proportions from the expression profiles ([@B62]). This method uses the first principal component obtained from the expression of a set of cell-type specific markers to estimate the relative abundance of a cell type. For cell-type markers, we used genes from a study of healthy temporal cortex tissue that was obtained during resective surgery ([@B16]). This study provided the top 21 most enriched genes for astrocytes, neurons, oligodendrocytes, oligodendrocyte precursors, microglia and endothelial cell-types (via transcriptomic clustering, Supplementary Table S3; ([@B16])). Default parameters for the mgpEstimate function were used with the geneTransform function set to the identity function. Proportions were estimated separately for each donor brain. Within a brain, proportions were mean averaged across multiple samples for each brain region. Regional proportions for each cell-type were then scaled and then mean averaged across the brains. Ranks were then computed across all regions for a specific cell-type to provide relative values of estimated proportions.

Gene Set Enrichment Analysis
----------------------------

To summarize the probe level statistics we used the probe to gene mappings provided by the Allen Institute ([@B37]; [@B68]). When many probes map to the same gene, we summarized the region-specific expression results by choosing the probe with the lowest *p*-value to represent the gene. For a given region of interest, *p*-values were combined with the direction of effect for the 20,779 genes (signed *p*-values). This provided a ranking from the gene with the most significant specific expression to the gene with the most significant depleted expression in the region. This genome-wide ranking allowed us to test if the genes that were specifically expressed in the habenula were enriched for a given gene set using the area under the receiver operator curve (AUROC) statistic. This non-parametric measure is frequently used for enrichment testing ([@B31]). The AUROC for a set of genes is equivalent to the probability that a gene associated with that set will be found first in the genome-wide ranking compared to an unassociated gene. The ranking we used arranges genes from strongest specific to depleted expression. In this context, AUROC \> 0.5 for a gene set means that these genes have specific expression in the habenula. For AUROC \< 0.5 the reverse is true, with a bias toward depleted expression in the habenula. Given our focus on up-regulation, we only examined groups with AUROC \> 0.5 (one-sided tests). AUROC values were generated using the tmod analysis package in R ([@B104]). The Mann--Whitney *U* test was used to determine statistical significance (one-sided). We used the Benjamini--Hochberg false discovery rate (FDR) procedure for multiple test correction ([@B3]) to adjust for the many tested gene sets. We performed no or limited multiple test correction for gene sets associated with depression and addiction. This *a priori* focus is marked by the inclusion of this article in the Frontiers Special Research Topic titled "Lateral Habenula: Role in Depression and Addiction".

We also employ a specificity test to determine if the enriched gene sets are not representing broad differences that are significant across many other brain regions. For example, habenula specific gene sets may simply represent expression differences between the cortex and the rest of the brain. To assess specificity we ran the region-specific expression and gene set enrichment procedures for 516 fetal and 217 named brain regions in the expression datasets. For each gene set, we counted the number of regions with an AUROC value higher than the habenula result. Gene sets that have the highest specificity in the habenula subregions were considered to uniquely characterize the region.

Gene Ontology Sets
------------------

The Gene Ontology (GO) classifies genes into sets associated with specific biological processes, molecular functions, and cellular locations to formally model biological systems ([@B2]). The GO database was accessed through the GO.db and org.Hs.eg.db packages in R ([@B9],[@B10]). Annotations were dated March 29, 2017. We calculated the AUROC values for GO groups containing between 10 and 200 genes, after filtering for genes present in the Allen microarray data (6,623 GO groups annotating 14,530 unique genes).

Disease-Associated Gene Sets
----------------------------

Disease-associated gene sets were obtained from the DisGeNET database which integrates several sources ([@B84]). The curated gene-disease association file was downloaded in May 2018. Similar to the GO sets, we filtered for disease-associated gene sets with 10 to 200 genes after the intersection with our results (1,849 disease-associated gene sets covering 5,899 unique genes).

To complement the heterogeneous mix of sources in the DisGeNET we obtained genes from five large genetic studies focused on addiction or depression. For cannabis associated genes we used the seven genes harboring the genome-wide significant loci from the analysis of lifetime cannabis use \[Table 1 in ([@B81])\]. We additionally used the 35 genes that were significant in the gene-based analysis from Table 2 (genes found in the S-PrediXcan analysis only were excluded because they were linked to a specific tissue). The nine genes near the 14 genome-wide loci associated with alcohol consumption were obtained from Table 1 of [@B13]. Genes associated with smoking were obtained from [@B69]. Specifically, genes associated with ever smoking (3 genes), quantity smoked (14) and smoking cessation (2) were obtained from Table 1. Four genes linked to substance use disorder and five associated with opioid use disorder were obtained from Table 1 in a review of genetic studies by [@B45]. For depression, we used the 71 genes that harbor the 44 significant loci identified in the largest genetic study of major depression to date \[Table 2 in ([@B106])\].

We additionally tested genes from transcriptomic studies of well-being and depression. These studies examined gene expression profiles of blood. The 27 genes from a study of recurrent major depression by [@B74] were split into up- and down- regulated lists (Table 2). For well-being, genes associated with hedonic well-being were obtained from Supplementary File D01 of [@B27].

Availability
------------

Scripts, supplementary tables, and data files for reproducing the analyses are available online at <https://github.com/leonfrench/HumanHabenula> and <https://figshare.com/articles/Transcriptomic_characterization_of_the_human_habenula_highlights_drug_metabolism_and_the_neuroimmune_system/6756728>.

Results
=======

Lateral Habenula
----------------

We first tested for specific expression in the lateral habenula in the adult brain data. Of the 48,170 tested microarray probes, 514 were significantly up-regulated in the lateral habenula (p~FDR~ \< 0.05, Supplementary Table S1). These probes mapped to 405 genes, with the top 20 presented in Table [1](#T1){ref-type="table"}. Both of the probes mapping to the most significant gene, GPR151, separate habenula from all other assayed structures (Figure [1A](#F1){ref-type="fig"}). In the fetal brain, 184 probes were significantly upregulated, representing 127 genes. Four genes were in both the fetal and adult top 20 most significantly up-regulated lists (*GPR151*, *POU4F1*, *ONECUT1*, and *CHRNB3*). Strong overlap was observed more broadly with 42 genes significantly up-regulated in both the fetal and adult expression profiles of the lateral habenula (hypergeometric test, *p* \< 10^-39^).

###### 

Top 20 genes with specific expression in the adult lateral habenula.

  Gene symbol   Name                                                               Significant probes   *p*-value
  ------------- ------------------------------------------------------------------ -------------------- -----------
  GPR151        G protein-coupled receptor 151                                     2                    1.94E-85
  MMRN1         Multimerin 1                                                       2                    1.61E-68
  UGT2B15       UDP glucuronosyltransferase family 2 member B15                    1                    5.64E-36
  WNT3A         Wnt family member 3A                                               1                    3.87E-33
  POU4F1        POU class 4 homeobox 1                                             2                    6.61E-23
  AQP2          Aquaporin 2                                                        1                    6.3E-22
  PTCHD3        patched domain containing 3                                        1                    1.21E-21
  TRPM8         Transient receptor potential cation channel subfamily M member 8   2                    2.45E-21
  CYP3A5        Cytochrome P450 family 3 subfamily A member 5                      1                    4.55E-14
  ONECUT1       One cut homeobox 1                                                 2                    4.62E-14
  POU4F3        POU class 4 homeobox 3                                             1                    4.08E-13
  CPA1          Carboxypeptidase A1                                                1                    1.63E-12
  GNG8          G protein subunit gamma 8                                          2                    1.61E-11
  GALR1         Galanin receptor 1                                                 2                    2.16E-11
  CHRNB3        Cholinergic receptor nicotinic beta 3 subunit                      3                    3.44E-11
  ESM1          Endothelial cell specific molecule 1                               2                    4.32E-11
  GPR15         G protein-coupled receptor 15                                      1                    6.95E-11
  ENO3          Enolase 3                                                          1                    3.07E-10
  RCAN1         Regulator of calcineurin 1                                         2                    1.06E-09
  EGFR          Epidermal growth factor receptor                                   4                    2.24E-09
                                                                                                        

![Violin plots of *GPR151* expression in the adult **(A)** and fetal **(B)** brains. Expression (log~2~ intensity) is plotted on the *y*-axis for each of the two probes for *GPR151*. Donor identification numbers are marked in the *x*-axis. Expression in the lateral habenula is marked in black with orange marking the medial division. The distribution of expression across the remaining sampled regions is shown in blue.](fnins-12-00742-g001){#F1}

Medial Habenula
---------------

In the medial habenula, the 624 significant up-regulated probes mapped to 427 genes (p~FDR~ \< 0.05, Supplementary Table S2). *GPR151* was the most specifically expressed gene in both the fetal and adult data for the medial division (Figure [1](#F1){ref-type="fig"} and Table [2](#T2){ref-type="table"}). In the fetal brain, 924 probes that map to 624 genes were upregulated in the medial habenula. In comparison to the lateral habenula, there was a stronger overlap between the adult and fetal results. Specifically, six genes overlapped within the top 20 lists (*GPR151*, *CYP3A4*, *CYP3A5*, *POU4F1*, *CHRNB3*, and *CAPN8*) and 160 were in both sets of significantly upregulated genes (hypergeometric test, *p* \< 10^-132^).

###### 

Top 20 genes with specific expression in the adult medial habenula.

  Gene symbol   Name                                                               Significant probes   *p*-value
  ------------- ------------------------------------------------------------------ -------------------- -----------
  GPR151        G protein-coupled receptor 151                                     2                    1.74E-73
  PDE11A        Phosphodiesterase 11A                                              5                    1.62E-54
  TRPM8         Transient receptor potential cation channel subfamily M member 8   2                    3.09E-48
  GNG8          G protein subunit gamma 8                                          2                    1.1E-28
  ESM1          Endothelial cell specific molecule 1                               2                    7.34E-26
  CDC20B        Cell division cycle 20B                                            1                    7.27E-23
  CYP3A5        Cytochrome P450 family 3 subfamily A member 5                      1                    1.32E-21
  CHRNB4        Cholinergic receptor nicotinic beta 4 subunit                      2                    2.85E-21
  KLHDC4        Kelch domain containing 4                                          1                    3.15E-21
  WNT3A         Wnt family member 3A                                               1                    3.25E-21
  F13A1         Coagulation factor XIII A chain                                    2                    2.8E-18
  POU4F1        POU class 4 homeobox 1                                             2                    4.48E-18
  CYP3A4        Cytochrome P450 family 3 subfamily A member 4                      1                    8.49E-18
  CYP3A7        Cytochrome P450 family 3 subfamily A member 7                      2                    3.51E-17
  CHRNB3        Cholinergic receptor nicotinic beta 3 subunit                      3                    4.07E-17
  POU4F3        POU class 4 homeobox 3                                             1                    3.98E-16
  SAA1          Serum amyloid A1                                                   2                    2.76E-15
  CAPN8         Calpain 8                                                          2                    4.83E-15
  ABCA13        ATP binding cassette subfamily A member 13                         1                    5.79E-14
  ONECUT1       One cut homeobox 1                                                 2                    2.65E-12
                                                                                                        

Cytochrome P450 Isoenzymes
--------------------------

Surprisingly, three of the four members of the cytochrome P450 family 3 subfamily A, were in the top 20 most significantly up-regulated genes for the medial habenula (*CYP3A4*, *CYP3A5*, and *CYP3A7*; Table [2](#T2){ref-type="table"}). *CYP3A4* and *CYP3A5* were also in the fetal top 20 (mapped probes are plotted in Figure [2](#F2){ref-type="fig"}). This finding is unique as none of the other 217 brain regions have 3 or more of the 61 cytochrome P450 genes in their top 20 lists (*CYP3A5* is in the lateral habenula top 20, adult data).

![Violin plots of *CYP3A4* and *CYP3A5* expression in the adult **(A)** and fetal **(B)** brains. Expression (log~2~ intensity) is plotted individually for each probe on the *y*-axis (gene symbols in parenthesis). Donor identification numbers are marked in the *x*-axis. Expression in the lateral habenula is marked in black with orange marking the medial division. The distribution of expression across the remaining brain regions is shown in blue.](fnins-12-00742-g002){#F2}

We extended this finding genome-wide by using the AUROC method to test the complete ranking of genes. Specifically, AUROC for the 61 cytochrome P450 genes was greater than 0.59 in the lateral and medial habenula (both *p* \< 0.01). The four CYP3A subfamily genes had a stronger enrichment signal with AUROC above 0.85 in both divisions (*p* \< 0.005). In the context of the other brain regions, only 5 other regions have higher AUROC values for the CYP3A genes. We named this count of brain-wide relative enrichment the "specificity rank" (lower is more specific). While the broad cytochrome P450 signal was not strong in the fetal data (both AUROC = 0.55, *p* \> 0.08), the 3A subfamily genes were enriched in both divisions of the developing habenula (AUROC \> 0.89, *p* \< 0.005, specificity rank \< 27). Across both divisions and datasets, *CYP3A4*, *CYP3A5*, and *CYP3A7* were consistently ranked within the top 227 most enriched genes while *CYP3A43* shows little enrichment (ranked within the top 6,444--11,744 genes). In summary, the CYP3A genes were specifically expressed in the fetal and adult habenula.

Estimated Cell Type Proportions
-------------------------------

We next used the markerGeneProfile tool to estimate cell-type proportions ([@B62]). These estimates were built from top marker genes obtained from a study of the adult human temporal cortex. Due to the difference in brain region, we only used the estimates to roughly characterize the cell-type composition of the habenula in the context of the other regions in the adult expression atlas. For both divisions, microglia had the highest estimated proportion with 15 and 18 regions having a higher estimate for the lateral and medial habenula, respectively. Astrocyte (specificity rank = 33) and endothelial cells (specificity rank = 35) also had above average estimated proportions the lateral habenula. In the medial habenula, endothelial cells were enriched (specificity rank = 58) with the remaining four cell types with above average estimated proportions (Supplementary Table S3).

Addiction Focused Gene Set Enrichment Analyses
----------------------------------------------

First, we tested GO terms related to drugs of abuse for enrichment in the adult habenula. Genes that were annotated to amphetamine, morphine, or cocaine response were not significantly enriched in the lateral or medial adult habenula (27--51 genes per group). The 47 genes annotated with the response to nicotine term were significantly enriched in the lateral (AUROC = 0.653, *p*~uncorrected~ \< 0.00015) and medial habenula (AUROC = 0.614, *p*~uncorrected~ \< 0.005). Brain-wide, this enrichment was specific with lateral habenula having the highest AUROC value of all 217 regions tested (specificity rank = 0). The medial finding was also relatively unique with a specificity rank of 10 (which includes the lateral habenula). Genes annotated to the response to alcohol term were significantly enriched in the medial (187 genes, AUROC = 0.54, *p*~uncorrected~ \< 0.02, specificity rank = 30), but not the lateral habenula. In total, 12 GO terms have alcohol in their title. Of those terms, genes annotated to positive regulation of alcohol biosynthetic process were significantly enriched in both the medial and lateral habenula after correcting for the 12 tests (p~FDR~ \< 0.005, AUROC \> 0.67, specificity rank \< 6). An additional two terms were enriched in the lateral but not medial habenula ('regulation of alcohol biosynthetic process' and 'primary alcohol metabolic process').

We next tested disease annotations related to addiction using the adult data. Of the eight gene sets with alcohol in their title, none were significantly enriched in the medial habenula and three had significant enrichment without correction for multiple testing in the lateral division (Non-alcoholic Fatty Liver Disease, Fetal Alcohol Spectrum Disorders and Fetal Alcohol Syndrome; *p*~uncorrected~ \< 0.05 and p~FDR~ \< 0.08). No significant enrichment was found for marijuana, cocaine or amphetamine abuse or dependence related gene sets.

To complement the disease associations from the DisGeNet database we tested genes from large genome-wide association studies of addiction. For addiction associated gene sets, none were significantly enriched after multiple test correction for the eight sets in the medial or lateral adult habenula data. For the lateral habenula, two genes associated with smoking cessation (*SLC25A21* \[ranked 848\], *SEMA6D* \[ranked 1128\], *p*~uncorrected~ \< 0.02, AUROC = 0.95, specificity rank = 4), 14 associated with quantity of cigarettes smoked (*p*~uncorrected~ \< 0.03, AUROC = 0.65, specificity rank = 13) and four genes associated with broad illicit drug use (*p*~uncorrected~ \< 0.05, AUROC = 0.75, specificity rank = 3) were nominally enriched. The habenula specific genes associated with quantity smoked were cholinergic receptors (*CHRNA3* and *CHRNB4*) and major histocompatibility complex proteins (*HLA-DPA1* and *HLA-DPB1*). For the fetal lateral habenula, only the seven cannabis associated genes were enriched (*p*~uncorrected~ \< 0.01, AUROC = 0.77, specificity rank = 12). For the medial division in the adult dataset, the four genes associated with broad illicit drug use were the most enriched and specific (*p*~uncorrected~ \< 0.02, AUROC = 0.84, specificity rank = 0). The two smoking cessation associated genes, *SLC25A21* (ranked: 1021) and *SEMA6D* (ranked: 4285), were also enriched in the medial habenula data (*p*~uncorrected~ \< 0.04, AUROC = 0.87, specificity rank = 20). These two sets were also enriched in the fetal data (*p*~uncorrected~ \< 0.05 for both). The top-ranked set in the fetal medial data were the genes associated with quantity of cigarettes smoked (14 genes, *p*~uncorrected~ \< 0.005, p~FDR~ \< 0.04 \[corrected for 8 sets\], AUROC = 0.7, specificity rank = 6). Thus, some enrichment was observed for the genes harboring genetic variants associated with broad illicit drug use, cannabis, and smoking but not for alcohol consumption or opioid use.

Depression Focused Gene Set Enrichment Analyses
-----------------------------------------------

Of the four disease gene sets from DisGeNet that are related to depression, only "Depressive Symptoms" was significantly enriched for lateral habenula specific expression (29 genes, AUROC = 0.6, *p*~uncorrected~ \< 0.05, specificity rank = 0). Genes harboring genetic loci that were associated with major depressive disorder in the largest genetic study to date were not enriched in the medial or lateral habenula ([@B106]). This enrichment for depressive symptoms and the central role of the habenula in the hedonic neurocircuit motivated an analysis of genes that were differentially expressed in a study of well-being ([@B33]). Genes that were up-regulated in the blood of people with low levels of hedonic well-being were enriched in both divisions of the adult habenula (33 genes, *p* \< 0.0005, AUROC \> 0.67, specificity rank \< 7, Figure [3](#F3){ref-type="fig"}). These genes that were negatively correlated with hedonic well-being were also enriched in the fetal medial habenula (*p* \< 0.005, specificity rank = 1). In contrast, no significant enrichment was observed for genes up-regulated with hedonic well-being or genes differentially expressed in blood of individuals with recurrent major depression. Overall, we found enrichment for genes associated with depressive symptoms, including hedonic well-being but not genes linked to major depressive disorder.

![Associations between genes that are down-regulated in the blood of people with high levels of hedonic well-being and habenular specific expression. **(A)** ROC curves showing the proportion of hedonia down-regulated genes that overlap (*y*-axis, true positive fraction) in varying lengths of the habenula specific gene rankings (approximated by the *x*-axis, false positive fraction). **(B)** Distributions of the hedonia down-regulated genes across the habenular specific gene rankings with each gene representing a single colored line. Color marks the lateral (black) and medial (orange) habenula rankings. Dashed lines are used for the fetal datasets.](fnins-12-00742-g003){#F3}

Gene Ontology Enrichment
------------------------

We next used all the Gene Ontology annotations to obtain a broader characterization of the molecular functions, cellular components, and biological processes with high expression in the habenula. We applied the same procedures used for the above analyses with the addition of multiple test correction for the 6,623 GO groups used. For the lateral habenula, 981 groups were significant after correction and the top enriched GO groups cover a broad range of annotations (full list in Supplementary Table S4). The top result was the 196 genes annotated to the humoral immune response (p~FDR~ \< 10^-11^, AUROC \> 0.66, specificity rank = 3). Ten immune-related GO groups also appear within the top 15 with other groups representing peptidase regulation, glycosaminoglycan binding, odorant binding, and G-protein coupled peptide receptor activity (all p~FDR~ \< 10^-7^, specificity rank \< 13). For the medial habenula, 333 groups were significant after multiple test correction (full list in Supplementary Table S5). The most significant group was cilium movement (60 genes, p~FDR~ \< 10^-10^, AUROC \> 0.79, specificity rank = 4), which was joined by five other cilium or axoneme related gene sets in the top 15. This enrichment for cilia associated genes was expected because the medial habenula borders the 3rd ventricle. Within that top list, the remaining groups were immune (regulation of mononuclear cell proliferation and response to interferon-gamma) or nucleosome related (all p~FDR~ \< 10^-5^, specificity rank \< 37). Comparing the top 15 GO groups for the lateral and medial divisions revealed four shared immune-related groups: response to interferon-gamma, MHC protein complex, regulation of mononuclear cell proliferation and regulation of lymphocyte proliferation. Overall, stronger enrichment was found in the lateral habenula but this may be due to differing sample sizes (3 lateral versus 2 medial samples).

To filter the large number of significant GO groups, we selected groups that have a higher AUROC value than any other assayed region and were also enriched in the fetal samples (specificity rank = 0 and fetal *p*~uncorrected~ \< 0.05). In the lateral habenula, applying the specificity leaves 114 of the 981 significant groups. As shown in Table [3](#T3){ref-type="table"}, 38 groups were also enriched in the fetal brain samples (binomial test *p* \< 10^-16^). While this list was primarily immune-related, acetylcholine binding and response to nicotine also appear. For the medial habenula, only four groups survive this filter (Table [4](#T4){ref-type="table"}). To provide an extended list, we relaxed the specificity criteria to allow the gene group to have a higher AUROC value in one other brain region (specificity rank ≤ 1). Of the 31 groups with this specificity level, 22 were also significantly enriched in the fetal medial habenula at an *p*~uncorrected~ of 0.05 or lower (binomial test *p* \< 10^-16^). These groups were primarily immune-related but also include two groups related to apoptosis via cysteine-type endopeptidase activity (Table [4](#T4){ref-type="table"}).

###### 

Gene Ontology (GO) groups enriched for uniquely specific expression in the adult lateral habenula which validate in the fetal brain.

  Name                                                       Genes   AUROC   Specificity rank   *p*-value~FDR~   Fetal AUROC   Fetal *p*-value
  ---------------------------------------------------------- ------- ------- ------------------ ---------------- ------------- -----------------
  Glycosaminoglycan binding                                  200     0.643   0                  2.21E-09         0.586         1.49E-05
  Cytokine receptor activity                                 91      0.705   0                  5.22E-09         0.598         0.000624
  Leukocyte chemotaxis                                       188     0.641   0                  7.17E-09         0.544         0.0195
  Negative regulation of cell activation                     162     0.643   0                  7.24E-08         0.551         0.0126
  Acute inflammatory response                                129     0.658   0                  9.44E-08         0.584         0.000486
  Myeloid leukocyte migration                                164     0.64    0                  1.03E-07         0.539         0.0447
  Positive regulation of epithelial cell proliferation       161     0.629   0                  1.79E-06         0.544         0.0266
  Positive regulation of chemotaxis                          127     0.642   0                  3.17E-06         0.566         0.00526
  Negative regulation of cell-cell adhesion                  137     0.633   0                  6.69E-06         0.558         0.0101
  Immunoglobulin binding                                     21      0.834   0                  7.95E-06         0.671         0.00336
  Mast cell activation                                       55      0.695   0                  2.66E-05         0.571         0.034
  Regulation of alpha-beta T cell activation                 74      0.666   0                  3.62E-05         0.581         0.00775
  Regulation of acute inflammatory response                  70      0.665   0                  6.83E-05         0.591         0.00408
  Alpha-beta T cell proliferation                            27      0.764   0                  7.46E-05         0.605         0.0297
  Regulation of phosphatidylinositol 3-kinase signaling      145     0.61    0                  0.000143         0.543         0.0363
  Phosphatidylinositol 3-kinase signaling                    163     0.602   0                  0.000219         0.539         0.0414
  Formation of primary germ layer                            119     0.616   0                  0.00032          0.556         0.0169
  Positive regulation of lymphocyte differentiation          84      0.634   0                  0.000483         0.576         0.0083
  Regulation of humoral immune response                      47      0.678   0                  0.000549         0.575         0.0374
  Negative regulation of leukocyte mediated immunity         44      0.681   0                  0.000693         0.586         0.0245
  Regulation of alpha-beta T cell proliferation              23      0.745   0                  0.000896         0.614         0.0297
  Acetylcholine binding                                      17      0.763   0                  0.00225          0.69          0.00328
  Icosanoid secretion                                        43      0.664   0                  0.00243          0.592         0.0185
  Collagen fibril organization                               38      0.675   0                  0.00243          0.592         0.0247
  Response to nicotine                                       47      0.653   0                  0.0033           0.571         0.0468
  Anion:cation symporter activity                            49      0.647   0                  0.00393          0.596         0.00997
  Positive regulation of mast cell activation                15      0.762   0                  0.00429          0.637         0.0335
  Peptide hormone processing                                 33      0.676   0                  0.00458          0.617         0.0101
  Acetylcholine-gated cation-selective channel activity      16      0.749   0                  0.00515          0.625         0.0418
  Branch elongation of an epithelium                         20      0.721   0                  0.00536          0.627         0.0242
  Regulation of cell fate commitment                         28      0.687   0                  0.0054           0.614         0.0187
  Acetylcholine receptor activity                            22      0.711   0                  0.00542          0.676         0.00215
  Neurotransmitter transporter activity                      25      0.696   0                  0.00585          0.629         0.0126
  Neurotransmitter:sodium symporter activity                 19      0.72    0                  0.00703          0.618         0.038
  Regulation of T cell apoptotic process                     32      0.666   0                  0.00841          0.593         0.0348
  Positive regulation of alpha-beta T cell differentiation   38      0.644   0                  0.0128           0.589         0.0295
  Neurotransmitter binding                                   22      0.673   0                  0.0229           0.623         0.0229
  Endodermal cell differentiation                            45      0.615   0                  0.0324           0.634         0.000942
                                                                                                                               

###### 

Gene Ontology groups enriched for uniquely specific expression in the adult medial habenula which validate in the fetal brain.

  Name                                                                           Genes   AUROC   Specificity Rank   *p*-value~FDR~   Fetal AUROC   Fetal *p*-value
  ------------------------------------------------------------------------------ ------- ------- ------------------ ---------------- ------------- -----------------
  Positive regulation of leukocyte differentiation                               132     0.639   1                  6.56E-06         0.614         3.28E-06
  Positive regulation of hemopoiesis                                             163     0.623   1                  1.08E-05         0.588         5.15E-05
  Regulation of B cell activation                                                108     0.625   0                  0.000658         0.578         0.00268
  Positive regulation of tumor necrosis factor superfamily cytokine production   59      0.666   1                  0.000786         0.691         2.03E-07
  Positive regulation of lymphocyte differentiation                              84      0.634   1                  0.00124          0.627         2.81E-05
  Positive regulation of immune effector process                                 160     0.595   1                  0.00167          0.592         2.86E-05
  Cysteine-type endopeptidase activity involved in apoptotic process             15      0.787   1                  0.00428          0.758         0.00027
  Positive regulation of myeloid cell differentiation                            80      0.622   1                  0.00543          0.582         0.00574
  B cell receptor signaling pathway                                              46      0.659   1                  0.00603          0.623         0.00196
  Microglial cell activation                                                     18      0.753   1                  0.00645          0.639         0.0204
  Regulation of antigen processing and presentation                              16      0.768   1                  0.00645          0.706         0.00219
  Positive regulation of myeloid leukocyte differentiation                       50      0.65    1                  0.0071           0.622         0.00142
  Positive regulation of interleukin-6 production                                66      0.626   1                  0.0102           0.594         0.00422
  Cysteine-type endopeptidase regulator activity involved in apoptotic process   43      0.654   1                  0.0117           0.603         0.00972
  Negative regulation of B cell activation                                       29      0.686   1                  0.0125           0.609         0.0209
  Positive regulation of CD4-positive, alpha-beta T cell activation              29      0.679   0                  0.0166           0.661         0.00133
  Positive regulation of cellular extravasation                                  13      0.76    0                  0.0199           0.71          0.00433
  Positive regulation of myotube differentiation                                 30      0.663   0                  0.0288           0.595         0.0354
  Granulocyte macrophage colony-stimulating factor production                    15      0.727   1                  0.0316           0.652         0.0206
  Regulation of odontogenesis of dentin-containing tooth                         13      0.742   1                  0.0332           0.681         0.012
  Positive regulation of CD4-positive, alpha-beta T cell differentiation         25      0.668   1                  0.0406           0.665         0.00221
  Positive regulation of adaptive immune response                                80      0.591   1                  0.0495           0.585         0.0044
                                                                                                                                                   

Disease-Associated Gene Enrichment
----------------------------------

Beyond the addiction and depression sets of interest, several disease-associated gene sets ranked higher. Of the 1,849 tested sets, the top 10 most enriched in the lateral habenula are presented in Table [5](#T5){ref-type="table"} and include disorders that often result from addictions (Table [5](#T5){ref-type="table"}, full list in Supplementary Table S6). In agreement with the gene ontology results, the top diseases for the medial habenula were primarily related to cilium dysfunction (Supplementary Table S7). Four diseases occurred in the top ten for both divisions (influenza, pneumonia, calcinosis and IgA glomerulonephritis).

###### 

Top 10 disease-associated gene sets enriched for specific expression in the adult lateral habenula.

  Name                     Genes   AUROC   Specificity Rank   *p*-value~FDR~
  ------------------------ ------- ------- ------------------ ----------------
  Influenza                52      0.731   8                  8.09E-06
  Pneumonia                88      0.664   0                  5.3E-05
  Rheumatoid arthritis     172     0.616   0                  6.21E-05
  Calcinosis               45      0.716   0                  0.000137
  IgA glomerulonephritis   36      0.732   1                  0.000285
  Hypersensitivity         62      0.669   5                  0.000661
  Multiple sclerosis       38      0.698   2                  0.00317
  Uremia                   17      0.789   0                  0.00417
  Pulmonary fibrosis       80      0.633   1                  0.00417
  Liver cirrhosis          130     0.604   2                  0.00417
                                                              

Discussion
==========

This study characterized the human lateral and medial habenula at the molecular scale. We tested for specific enrichment of genes associated with addiction and depression before performing a broader analysis. In agreement with a single-cell expression study of the larval and adult zebrafish habenula, our findings significantly overlapped between the adult and fetal results ([@B79]). While focused on the adult habenula, we used the fetal data to validate key findings. Data from other brain regions was also used to determine specificity. In summary, we found the habenula specifically expressed genes associated with nicotine and smoking; cannabis; drug metabolism and clearance; acute immune response, mast cells, and inflammatory diseases; cilium; hedonic well-being; and hematopoiesis. We did not find strong or specific enrichment of genes associated with other drugs of abuse; learning, memory, and attention; nor major depressive disorder.

Top-Ranked Genes
----------------

At the level of individual genes, we found the expected enrichment of cholinergic receptors with the nicotinic β3 and β4 subunits having the highest specificity in the lateral and medial division, respectively. Supporting translational potential, the β4 subunit was shown to limit nicotinic acetylcholine receptor activity and regulate nicotine aversion in studies of the mouse medial habenula ([@B26]; [@B96]). Combined, the 17 genes in the acetylcholine binding GO group that encode 14 nicotinic subunits, the muscarinic 3 receptor, acetylcholinesterase, and solute carrier family 18 member A3 (acetylcholine transporter) are specifically and uniquely enriched in the lateral habenula. However, the medial habenula had a higher number of significantly enriched cholinergic receptor genes after multiple test correction (nicotinic subunits α3, α4, α6, and β4). In the mouse medial habenula, receptors containing the α6 subunit were involved in nicotine withdrawal-induced anxiety ([@B80]). While habenular α5 subunit signaling has been shown to limit nicotine intake in rats, *CHRNA5* is not specifically expressed in the human habenula ([@B25]). A recent mouse study suggests the α5 subunit may be important for nicotine preference and aversion in another region, the interpeduncular nucleus, which receives inputs from the medial habenula ([@B1]; [@B73]).

Confirming animal expression studies ([@B8]; [@B102]), the most specifically expressed gene in the habenula is a G protein-coupled receptor 151 (*GPR151*) which separated habenula expression from any other assayed region in the adult data. Similarly, specific expression of *GPR139* was observed, in agreement with rat and human expression patterns ([@B57]) (75th and 168th most specific gene the lateral and medial habenula, respectively). A recent study demonstrated that activation of GPR139 reduces alcohol intake in alcohol-dependent rats ([@B49]). Transient Receptor Potential Cation Channel Subfamily M Member 8 (*TRPM8*), was highly expressed in both the lateral and medial habenula (ranked 3rd and 8th in the medial and lateral divisions, respectively). This gene encodes a cation channel which is activated by menthol, providing a candidate molecule for studies examining the neurobiological effects of menthol on cigarette smokers ([@B29]; [@B7]; [@B38]). Overall, the top-ranked genes confirm rodent studies and mark targets for future studies of addiction.

Cytochrome P450 Enzymes and Drug Metabolism
-------------------------------------------

Genes encoding cytochrome P450 enzymes were highly expressed in the medial habenula which has also been observed in rodent studies ([@B78]; [@B5]). The metabolic functions of P450 enzymes are required to clear foreign and toxic compounds from the body. P450 substrates include therapeutic drugs, toxins, carcinogens, and some endogenous molecules that include testosterone and estrogen. For example, Cytochrome P450 Family 3 Subfamily A Member 4 (*CYP3A4*) is estimated to be involved in the metabolism of over half of all therapeutic drugs ([@B43]; [@B89]). This is of note as *CYP3A4* was the 13th most specifically expressed gene for the adult medial habenula. For *CYP3A7*, we found more specific habenular expression in the adult when compared to the fetal data, which contrasts studies of the liver that found high fetal expression ([@B36]). In addition, UDP Glucuronosyltransferase Family 2 Member B15 (*UGT2B15*), the 3rd most specifically expressed gene in the lateral habenula, is also involved in the elimination of toxic compounds (xenobiotic and endogenous) ([@B97]). Furthermore, *ADH7*, an alcohol dehydrogenase gene was enriched in the medial habenula (27th most specific gene). The combination of these enriched genes and the habenular border with the third ventricle suggest the habenula is uniquely sensitive to endogenous and xenobiotic compounds. This agrees with studies finding that the habenula is important for learning the adverse effects of drugs such as ethanol and nicotine ([@B24]; [@B34]). Beyond drugs of abuse, this association with drug metabolism may underlie links between therapeutic drugs and depression that are of increasing importance ([@B82]; [@B87]).

Mast Cells and Neuroimmune Associations
---------------------------------------

In the lateral habenula, genes annotated to mast cell activation were uniquely and specifically enriched as a set. Mast cells are first responders of the immune system, reside in the brain, and can cross the blood--brain barrier ([@B19]). Mast cells contain granules that can quickly release their stored contents in response to external stimuli. The contents of these granules are packed together with the help of glycosaminoglycans ([@B76]). Genes that bind glycosaminoglycan were the most significant and specifically enriched gene set in the lateral habenula. Mast cells respond to steroids and regulate the blood-brain barrier in the medial habenula of doves ([@B109]; [@B105]). Mast cells react to xenobiotics, have been proposed as a paradigm for testing toxic effects of neurotropic drugs, and have been suggested to have detoxifying roles in the brain ([@B42]; [@B86]). More directly, habenular mast cells numbers are increased when rats are injected with cyclophosphamide, a toxic immunosuppressant and chemotherapeutic drug ([@B93]). This mast cell response was coupled with suppression of motor behavior. This key study connects our findings of enrichment of drug metabolism and mast cell associated genes with the habenula in an experimental setting.

Consistent with habenula being a source in negative reward signals, mast cells respond to aversive stimuli such as toxins, venoms, and physical stimuli ([@B28]; [@B46]). Central nervous system mast cells are also associated with chronic subordination stress ([@B12]) and anxiety ([@B77]). Patients with mastocytosis, a condition in which mast cells accumulate, are more likely to be depressed ([@B75]). A study of mastocytosis patients has also associated inflammatory markers with high depression scores ([@B30]). In the context of addiction, naloxone-induced morphine withdrawal increases mast cell numbers in the thalamus ([@B99]) and intravenous heroin increases markers of mast cell degranulation ([@B90]). Overall, our findings suggest that the habenula is a key location for neuroimmune interactions ([@B23]).

Beyond mast cells, we also observed enrichment of primarily immune-associated gene sets in Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}. This can be partly explained by the relatively high estimated proportion of microglia cells. While 15 regions had higher estimated proportions of microglia these immune-associated gene sets were most strongly enriched in the habenula (specificity rank = 0), suggesting that these signals were not merely due to higher proportions of microglia. In agreement, a past study of the Interleukin 18 cytokine observed expression in medial habenula neurons ([@B98]). One of most strongly enriched gene groups was 'response to interferon-gamma,' which is of interest given the recent associations between interferon-γ and social behavior ([@B22]). Interferon-γ is also expressed in habenular neurons after influenza infection ([@B72]). Two other gene sets of note are 'myeloid leukocyte migration' and 'positive regulation of cellular extravasation' which supports findings of brain leukocyte infiltration from the cerebrospinal fluid into the habenula and other regions in rodents ([@B91]). More specific studies that have focused on pro-inflammatory molecules have associated the habenula with depressive symptoms and chronic restraint stress ([@B98]; [@B107]). Recent advances in single-cell sequencing may help determine which cell-types are contributing to this unique neuroimmune signature in the habenula.

Depression
----------

Genes associated with major depressive disorder that were identified in the largest genome-wide association study to date were not specifically expressed in the habenula ([@B106]). In addition, genes differentially expressed in the blood of individuals with recurrent major depression in comparison to controls ([@B74]), were not specifically expressed in the habenula. Genes associated with depressive symptoms in the DisGeNet database were specifically and uniquely enriched in the lateral habenula. Also, genes negatively correlated with hedonic well-being were enriched in the medial and lateral habenula. This finding links the habenula to anhedonia, a key symptom of depression. Genes positively correlated with hedonic well-being were not enriched, suggesting the leukocyte source of these correlated genes was not driving the signal. In support, several studies have associated the habenula with hedonic pathways. In mice, the medial habenula was shown to regulate of hedonic state ([@B41]). In patients with cancer-associated weight loss reduced functional connectivity was observed between the habenula and nucleus accumbens during a reward task ([@B61]). Differences in habenula volume has been associated with anhedonia symptoms in depressed and healthy individuals ([@B52]). Habenula activation during a punishment task in unmedicated major depressive disorder patients was more strongly associated with anhedonia than overall depressive symptoms ([@B58]). Overall, we observed molecular associations with depressive symptoms and hedonic well-being but not genes directly linked to major depressive disorder.

Our broad analysis of disease-associated gene sets provided indirect links to depression. In the lateral habenula, we observed enrichment of several inflammatory diseases that align with the gene ontology analysis. In the context of depression, we note that that neuroinflammation has been associated with depression in mouse and human studies ([@B66]; [@B94]; [@B107]). Genes associated with rheumatoid arthritis were the third most enriched set with no other region having a stronger association. A meta-analysis found that patients with rheumatoid arthritis have a higher prevalence of depression ([@B17]). Similarly, genes associated with multiple sclerosis were enriched in the lateral habenula and depression is more common in multiple sclerosis patients ([@B83]). In addition, mast cells were found to be essential for disease progression in a mouse model of multiple sclerosis ([@B92]). IgA glomerulonephritis, an inflammatory kidney disease, was the 5th most enriched disease gene set. Genes associated with uremia were also specifically enriched (8th most enriched), which results from loss of kidney function. In patients with chronic renal disease, depression is the most common psychiatric condition ([@B20]). Again, these results may be explained by a higher proportion of microglia in the habenula, but again we note that several other regions have a higher estimated number of microglia and these disease genes sets are very specific to the habenula. We also note that genes associated with influenza were top-ranked. Past studies have found that habenula neurons are selectively targeted by the influenza virus, resulting in behavioral changes after infection and clearance ([@B71], [@B72]; [@B4]). This suggests that neurons may underlie some of these inflammatory disease associations in the habenula. While these associations are interesting, more direct studies are needed to test the pathophysiological role of the habenula in these diseases.

Addiction
---------

Related to addiction and drugs of abuse we found limited specific expression in the habenula. We observed some enrichment of genes related to nicotine response and genetic studies of smoking behavior. Cannabis receptor 1 (*CNR1*) is significantly enriched in the adult lateral habenula and genes harboring genetic variants associated with cannabis use were enriched in the lateral division of the fetal brain but not the medial habenula in the adult or fetal data. In a rat model of nicotine addiction, habenular CB1 receptor activity in the habenula was linked to depressive-like behavior and recovery from nicotine dependence ([@B95]). In the context of nicotine, we note that the expression of molecules in regions that connect to the habenula play key roles. Specifically, rodent studies of glucagon-like peptide-1 in the nucleus tractus solitarius ([@B100]), dopamine D3 receptors in the basolateral amygdala ([@B48]), and corticotropin releasing factor receptor-1 in the interpeduncular nucleus ([@B108]) have linked nicotine intake, seeking, and withdrawal, respectively.

We found some habenular specific expression for genes involved in the regulation of alcohol biosynthesis but no enrichment of genes associated with alcohol consumption nor alcohol abuse. Also, we did not observe specific habenular expression of genes associated with amphetamine, morphine, or cocaine responses and related disorders. Past findings of increased habenula activity after administration of these drugs may be mediated by the cytochrome P450 enzymes. For example, the effect of cocaine on neurodevelopment was found to be mediated by *CYP3A5* ([@B56]). Also, the negative findings are possibly due to limited understanding of which molecules are involved in drug withdrawal and relapse, which the habenula is thought to play a key role ([@B101]; [@B60]).

In the context of addiction, we note that genes involved in the positive regulation of hemopoiesis are strongly enriched in the medial habenula. Hematopoiesis or hemopoiesis is the production of blood cells. A phenome-wide association study of clonal hematopoiesis has associated it with smoking, addiction and psychiatric disease ([@B110]). In addition, increases of several hematological factors which included cell type counts were observed in opium and heroin users ([@B35]). A related result was enrichment of genes associated with thrombosis (12th most significantly enriched disease gene set in the lateral habenula). In the context of addiction, deep vein thrombosis is frequently caused by intravenous drug use ([@B15]; [@B50]). We also note that several of the lateral habenula disease-associated gene sets are associated with addictions: pneumonia \[smoking and alcohol abuse ([@B32])\], liver cirrhosis (alcohol abuse), pulmonary fibrosis (smoking), arthritis (smoking), uremia and IgA glomerulonephritis \[cocaine and alcohol abuse ([@B11]; [@B44])\]. Our analysis cannot determine the role, if any, played by the habenula or the enriched genes in the pathophysiology of these diseases or their associations with substance abuse. Nonetheless, these links between habenular gene expression, hemopoiesis, and the sequelae of addictions suggest complex relationships that warrant further investigation.

Feeding and Energy Balance
--------------------------

An analysis of habenula specific expression in the rat brain highlighted genes associated with feeding and energy balance ([@B102]). Habenula activity has also been inversely associated with food hedonics in rodents ([@B47]). In our gene set analysis, we did not observe enrichment of genes associated with eating behavior or energy regulation. However, we note that melanocortin 4 receptor (*MC4R*), was the 26th most significantly enriched gene in the lateral habenula. In addition, the five genes in the FTO obesity cluster were significantly enriched in the medial habenula which is primarily driven by the iroquois homeobox 5 and 6 genes (AUROC = 0.82, specificity rank = 14). Beyond *MC4R* and the FTO cluster, which were the two most significant genetic loci associated with body mass index, a larger set of genes harboring genetic variants associated with body mass index were not enriched in the habenula ([@B59]). Therefore, molecular studies of the habenula in the context of obesity should target the melanocortin system and iroquois homeobox genes.

Conclusion
==========

Numerous review articles have focused on the habenula but few mention the immune system or drug metabolism. Our results highlighted these underappreciated aspects of the region, suggesting the habenula is tuned to respond to negative signals from acute infection or xenobiotic compounds. This suggests that future studies of the human habenula should test effects of medication use. Our focused analysis highlighted genes associated with nicotine and cannabis but we did not observe associations with other specific drugs beyond a signal associated with broad substance abuse. It's possible that habenular responses to these drugs may be mediated by the general drug metabolism genes that are enriched, or may be due to the limited understanding of the molecular mechanisms underlying withdrawal. Related to depression we observed an association with hedonic well-being but not broader depression. Across all diseases, we observed associations with inflammatory disorders which is mirrored by Gene Ontology analysis. While we estimate the habenula has an above average number of microglia, these specific neuroimmune associations are stronger and supported by animal studies. Overall, our results from the healthy brain suggest the habenula may be a key bridge to aid understanding of drug-induced depression and the role of inflammation in depression. More generally, our results suggest the habenula receives negative reward signals from immune and drug processing molecules. This is consistent with the habenular role in the "anti-reward" system.
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